In oestrogen receptor-α negative (ERα-) and positive (ERα+) breast cancers, the activation of CB2R by JWH-015 reduced breast cancer cell survival via blocking of the EGFR and insulin-like growth factor-1 receptor (IGF1R) pathways. The gene discussed is IGF1R; the disease is breast cancer.